Congress should be promoting, not discouraging, the development of biosimilars

Forbes

27 August 2019 - Drug prices continue to dominate the headlines, yet many of the policy ideas being considered in Congress will make things worse, not better.

Some of these ill-considered ideas would make grandiose changes to the U.S. health care system, such as allowing drug importation from Canada. If implemented, such ideas will worsen the quality of health care Americans receive. With respect to drug importation, as I previously argued, it “is merely a sound bite, not a serious solution to the ineffective drug pricing system”.

Rather than headline-grabbing reforms, other ideas propose nonsensical changes to esoteric corners of the health care system. Proposed changes to how the nongovernmental U.S. Pharmacopeia would oversee medicines fall into this category.

Read Forbes article

Michael Wonder

Posted by:

Michael Wonder